FY2020 EHE Supplements

The UCSF-Gladstone Center for AIDS Research (CFAR) and the UCSF Center for AIDS Prevention Studies (CAPS) announce the availability of supplement funding in support of the Ending the HIV Epidemic: A Plan for America (EHE) Initiative, through the 2020 EHE CFAR/ARC Supplement Announcement. See full announcement for more information. Research topics are as follows:

1. EHE Team-initiated Implementation Research (up to $200,000 for up to 1 year)
2. Reaching Cisgender Heterosexual Women with PrEP (up to $150,000 for up to 1 year)
3. Evaluating and Developing Data-Driven Messages and Communication Strategies for EHE (up to $150,000 for up to 1 year)

Each center is limited to submitting a maximum of four applications (two for topic 1; one each for topics 2 and 3); therefore we are conducting an internal competition to determine which applications will go forward for submission to the NIH. Below are instructions for submitting concept proposals for this opportunity. Contact lauren.sterling@ucsf.edu with questions.

Funding

Supplement awards are for up to one year with maximum funding per application as listed above in Direct Costs. Awards will be made as supplements to the CFAR grant.

Concept Proposal Application Process

To apply for this opportunity, please do the following:

1. PLEASE SUBMIT CONCEPT PROPOSALS ELECTRONICALLY by completing the online form and attaching ONE FILE (MS Word or Adobe PDF) that includes the following three components by 12:00 p.m. Wednesday, April 8, 2020:
   1. Cover letter with title of proposed project (maximum of 81 characters), name and contact information of Project Director, and name(s) and contact information of Mentor(s), if applicable. Please also address the following:
      1. Include a table listing the key personnel to participate in the proposed project, including the following information: Names, degrees, institutional affiliations, and roles in project.
      2. Include a brief description of how you have addressed the purpose of this opportunity and the eligibility requirements described in the announcement.
      3. If you are a current EHE awardee, please provide a brief description of progress made to date.
   2. Description of proposal (limit one page, Arial 11 font or equivalent) briefly addressing the following:
      1. Background and rationale for the proposal
      2. Activities to be undertaken
      3. Expected outcome of these activities (value-added)
      4. Expected follow-up plan upon completion of the project
      5. A description of how the supplement and follow-up plan are expected to achieve this outcome.
         • Most importantly, clearly indicate how the proposed research activities are expected to lead to the development of stated goals. Briefly describe the Implementation Logic Model and the framework or model used to support this, as well as communication plan.
         • References cited do not count towards the one page limit.
         • ​Applicants are strongly encouraged to review the review criteria listed in the full announcement.
   3. NIH-formatted Biosketch of Project Director. Please make sure to include past and current Research Support so that we can confirm Project Director eligibility.
      
      Please note that the webform will request a direct costs total estimate and a brief description of budget by cost category (salaries, benefits, supplies, equipment, travel, other services, subcontracts). Please be sure that the aims of the proposal can be achieved with the given budget. Refer to the NIH Grants Policy Statement regarding allowable and unallowable costs. Please note that subcontract indirect costs are allowable and do not count towards the direct cost limit. Contact Lauren Sterling (cc: Frank Fernandez) if you have any budgetary questions.

After selection of the finalists, budget and other business elements are due are due by Monday, May 11, and research plan must be final by Tuesday, May 19. Full applications will be submitted to NIH by the UCSF-Gladstone CFAR or the UCSF Center for AIDS Prevention Studies.